NX Development Corp (Louisville, KY) has developed the first and only FDA-approved optical imaging agent indicated in patients with high-grade gliomas (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery. The company exited in 2018 in a sale to SBI Pharma Co Ltd of Japan.
NX Development Corp
NX Development Corp (Louisville, KY) has developed the first and only FDA-approved optical imaging agent indicated in patients with high-grade gliomas (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery. The company exited in 2018 in a sale to SBI Pharma Co Ltd of Japan.
